

**Table S2.** Adaptive Radiotherapy Risk Profile

<b>Adaptive strategy – Risk Profile</b>			
	<b>Low risk</b>	<b>Intermediate risk</b>	<b>High risk</b>
Tumor localization	NCC/MS//HPC	<b>NPC/OPC/L</b>	<b>NPC/OPC/OCC/L</b>
Loose mask		<i>Loose mask detected in weeks 3-4</i>	<i>Loose mask detected during week 1</i>
BMI/B-body	<i>If initial weight &lt;100 kg</i>	<i>If initial weight &lt;100 kg</i>	<i>Initial weight &gt;100 kg</i>
CHRT		<i>no chemoradiation</i>	<i>chemoradiation</i>
Postoperative RT		No	Yes
Stage	<b>T1/N0</b>	<b>T2-T3 / &lt;N1</b>	<b>T3-T4 / N1-N3</b>
Parotid Glands		<i>parotid glands also move to the body midline during radiation therapy</i>	<i>parotid glands also move to the body midline during radiation therapy</i>
		<i>difference between the planning scan and the CBCT/MVCT are greater than 3mm on 3-4 consecutive scans at any point of the external contour</i>	<i>difference between the planning scan and the CBCT/MVCT are greater than 3mm on 3-4 consecutive scans at any point of the external contour</i>
Nodal Status		<i>Dominant pretreatment nodal in region II-IV</i>	<i>Dominant pretreatment nodal in region II-IV</i>
			<i>CTV moves outside the body during treatment</i>
			<i>CTV covering more than 10% of initial PG volume</i>
PTV			<i>PTV outside the Body during treatment &gt;3mm on 3-4 consecutive scans</i>
<b>Suggested control Replan-CT</b>	<b>Observation</b>	<b>2-5th week of treatment</b>	<b>3-5th week of treatment</b>

Abbreviations: H&N, head and neck; PG, parotid gland; CTV, clinical target volume; PTV, planning target volume; BMI, body mass index; CHRT, chemoradiotherapy; OPC, oropharyngeal cancer; OCC, oral cavity cancers; and Other (NPC, nasopharynx, L=larynx, HPC=hypopharynx, CUP=cancer of unknown primary, NCC=nasal cavity cancer, MS=maxillary sinus cancer).